Want to understand how these updates are formatted? Check-out the FAQ.

Have any feedback? I’d love to hear you from - connect with me on LinkedIn. 📣

Bayer wins MHRA approval for Kerendia (finerenone) targeting mineralocorticoid receptor for chronic heart failure
Small molecule, cardiovascular, mineralocorticoid receptor antagonist, heart failure, preserved ejection fraction - Read more

Travere Therapeutics receives FDA approval for FILSPARI (sparsentan) treating focal segmental glomerulosclerosis following Ph3 results
Small molecule, renal disease, dual receptor antagonist, focal segmental glomerulosclerosis, endothelin receptor, angiotensin receptor - Read more

AbbVie, Haisco Pharmaceutical partner on pain compounds development, up to $715M deal value
Licensing deal, pain management, neurological, milestone payments - Read more

Regeneron Pharmaceuticals, Telix partner on radiopharmaceuticals for cancer, $40M upfront, $4.3B potential milestones
Co-development, oncology, radiopharmaceuticals, antibody, milestone payments, solid tumors - Read more

Kazia Therapeutics in-licenses first-in-class SETDB1 inhibitor platform from QIMR Berghofer for oncology
Licensing deal, oncology, AI/ML, drug discovery, epigenetic - Read more

Science 2 Sales builds and runs the entire outbound engine (across email, LinkedIn, and cold calling) for companies selling into biotech & pharma - so your sales team stops researching and starts closing qualified meetings with the decision-makers who can actually sign.

When it comes to outbound lead gen - you get the meetings. We handle everything else.

Learn more and book a free strategy call on our website.

Eli Lilly's Jaypirca hits Ph3 endpoint for chronic lymphocytic leukemia in fixed-duration combination therapy
Small molecule, cancer, BTK inhibitor, chronic lymphocytic leukemia, combination therapy, fixed-duration treatment - Read more

SynOx Therapeutics plans FDA filing for emactuzumab targeting CSF-1 receptor in tenosynovial giant cell tumour after Ph3 success
Antibody, cancer, monoclonal antibody, tenosynovial giant cell tumour, CSF-1 receptor - Read more

Spyre Therapeutics' SPY001 shows promise in Ph2 ulcerative colitis trial with significant disease activity reduction
Small molecule, inflammatory bowel disease, ulcerative colitis, SPY001, remission - Read more

Revolution Medicines' daraxonrasib nearly doubles survival in Ph3 pancreatic cancer trial, reducing death risk 60%
Small molecule, cancer, RAS inhibitor, pancreatic cancer, KRAS G12 mutation, metastatic - Read more

BioNTech and DualityBio's trastuzumab pamirtecan shows 44% response rate in Ph2 HER2-positive endometrial cancer trial
Antibody-drug conjugate, cancer, endometrial cancer, HER2 target, topoisomerase inhibitor - Read more

Allogene Therapeutics' cema-cel shows 58% residual disease clearance in Ph2 large B cell lymphoma trial
Cell therapy, cancer, CAR-T, large B cell lymphoma, allogeneic, measurable residual disease - Read more

IDEAYA Biosciences and Servier's darovasertib delivers Ph2/3 success in metastatic uveal melanoma, heads to FDA
Small molecule, cancer, PKC inhibitor, uveal melanoma, combination therapy - Read more

Kelun-Biotech reports positive Ph2 results for sacituzumab tirumotecan targeting TROP2 in ovarian and cervical cancers
Antibody-drug conjugate, cancer, gynecologic oncology, ovarian cancer, cervical cancer, TROP2 target - Read more

Hoth Therapeutics' GDNF (glial cell-derived neurotrophic factor) shows positive preclinical results for metabolic-associated fatty liver disease
Protein therapy, metabolic, GDNF, fatty liver disease, gene expression modulation - Read more

Kailera plans $528.5M IPO to advance quartet of Chinese obesity assets
Obesity, GLP-1, small molecule, clinical-stage - Read more

Neomorph raises $100M Series B, pioneering molecular glue degraders for undruggable proteins
Molecular glue degraders, oncology, platform technology, clinical-stage, undruggable proteins - Read more

ProtierBiotech raises $2.45M Pre-Series A, advancing molecular glue-based cancer drug pipeline
Cancer, molecular glue platform, antibody-drug conjugates, multiple myeloma, preclinical - Read more

Sparian Biosciences receives $15M NIH grant, CNS-focused biopharmaceutical developing pain therapies
CNS-focused, clinical-stage, pain management, substance use disorders - Read more

DeepCyte raises $1.5M Seed, AI toxicology tools for drug development
AI/ML platform, toxicology, drug safety, single-cell analysis - Read more

ImageneBio raises $30M private placement, developing IMG-007 for alopecia areata treatment
Autoimmune, antibody, clinical-stage, dermatology - Read more

Do you offer a biotech/pharma-focused product or service?

Or looking to get investor/analyst interest on your budding start-up?

Considering sponsoring TLDR Biotech to get in-front of an engaged audience of biotech & pharma-focused professionals.

Just reply to this email* or message me on LinkedIn to learn more.

*If you’re reading this on the web version, email [email protected]

Retractable Technologies cuts 16% of workforce to save $2.2M annually amid tariff pressures
Medical devices, operational, cost reduction, financial - Read more

Have comments/questions/complaints about this newsletter?
Send me an email - I want your brutally honest feedback. 📝

If you find the content useful and think a colleague would too, please share TLDR Biotech with them! ♻️

And lastly - connect with me on LinkedIn!

Disclaimer: Content, news, research, tools, and mention of stock or tradeable securities are for educational and illustrative purposes only and do not imply a recommendation or solicitation to buy or sell a particular security or to engage in any particular investment strategy. Read the full terms & conditions here